Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss treatment selection in relapsed/refractory follicular lymphoma.
Back
Optimizing Sequencing Strategies in R/R Follicular Lymphoma
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss sequencing considerations in relapsed/refractory follicular lymphoma.
Optimizing Sequencing Strategies in R/R Follicular Lymphoma
Episodes
All
All
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss methods of building on the lenalidomide/rituximab backbone in relpased/refractory follicular lymphoma.
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss data for tafasitamab- and epcoritamab-based combinations in relapsed/refractory follicular lymphoma.
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss factors that can inform sequencing planning in follicular lymphoma management.
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss the role of targeted therapies and rechallenging with certain classes of agents in follicular lymphoma.
Loretta J. Nastoupil, MD, and Amitkumar Mehta, MD, discuss future research to watch in follicular lymphoma.
Advertisement
Advertisement
Trending on OncLive
1
Intismeran Autogene Plus Pembrolizumab Meets RFS and DMFS End Points in Resected Stage IIB-IV Melanoma
2
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
3
Mo-Rez Advances Into Combination Studies Following Robust Responses in Gynecologic Cancers
4
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
5